Skip to contentT
TELA Bio, Inc.
T
TELATELA Bio, Inc. Q3 2024 · 10-Q
Revenue$18.96M$18.96M+25.9% vs Q3 2023 Net Income-$10.37M-$10.37MN/M vs Q3 2023 EPS Diluted-$0.42-$0.42N/M vs Q3 2023 Gross Profit$12,858,000+23.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TELA Bio, Inc. · CIK 1561921 · Engraved from SEC EDGAR
Operating Cash Flowderived-$8,983,000N/M Free Cash Flowderived-$9,105,000N/M Margins · derivedGross margin67.8%−1.2 pt vs Q3 2023
Operating margin-49.4%+18.2 pt vs Q3 2023
Net margin-54.7%+18.1 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 8, 2024 · 39 d after period end